Parliamentary Search

Written question asked by Helen Hayes (Labour) on Thursday, 15 October 2020, in the House of Commons. It was due for an answer on Tuesday, 20 October 2020 (named day). A holding answer was provided on Tuesday, 20 October 2020. A substantive answer was provided by Edward Argar (Conservative) on Thursday, 12 November 2020 on behalf of the Department of Health and Social Care.

Roche: Blood Tests

Question

To ask the Secretary of State for Health and Social Care, what assessment his Department made of the performance of Roche Diagnostics in delivering blood testing for NHS England; and what the (a) key performance indicators and and (b) penalties are in NHS England's contract with that company to deliver those services.

Answer

NHS England and NHS Improvement have been meeting with the senior management team at Roche regularly, including representatives of the Department and the devolved administrations. A daily review of every pathology network in England, including South East London, takes place, with urgent issues raised directly to Roche for prioritisation.

The National Health Service’s commercial relationship with Roche is between pathology networks or individual NHS trusts and foundation trusts and the supplier. Key Performance Indicators and contract penalties sit within those individual, local contracts. NHS England and NHS Improvement are providing support to pathology networks to ensure any local contractual terms and conditions are applied correctly in light of the current incident. NHS England and NHS Improvement, along with counterparts in the devolved administrations, are working closely with Roche on the implementation and delivery of a recovery plan to restore normal supply to the pathology networks.

Secondary information

Type
Written question
Reference
104135
Session
2019-21
Grouped for answer
Yes
Subjects
Contracts Standards Blood tests Roche NHS England
Link
View this Written question on www.parliament.uk